Quick Answer
Foghorn Therapeutics Inc. reported Diluted EPS of $1.18 per share (loss) for fiscal year 2025.
Foghorn Therapeutics Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.18 | +25.3% |
| 2024 | -$1.58 | +32.5% |
| 2023 | -$2.34 | +10.7% |
| 2022 | -$2.62 | +4.0% |
| 2021 | -$2.73 | +56.2% |
| 2020 | -$6.23 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.25 | +19.4% | +10.7% |
| June 30, 2025 | -$0.28 | +37.8% | +6.7% |
| March 31, 2025 | -$0.30 | +49.2% | +3.2% |
| September 30, 2024 | -$0.31 | +8.8% | +31.1% |
| June 30, 2024 | -$0.45 | +35.7% | +23.7% |
| March 31, 2024 | -$0.59 | +19.2% | -73.5% |
| September 30, 2023 | -$0.34 | +45.2% | +51.4% |
| June 30, 2023 | -$0.70 | -6.1% | +4.1% |
- Foghorn Therapeutics Inc. showed an increase of +25.3% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Foghorn Therapeutics Inc.’s diluted eps has grown by 81.1% (from $6.23 per share (loss) to $1.18 per share (loss)).
- The most recent figure is from Foghorn Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: